DSIP (Emideltide): Sleep and Withdrawal Research, Safety, and Why PCAC Voted Against It

Summary: Emideltide, commonly called delta sleep-inducing peptide or DSIP, is a nine-amino-acid peptide historically studied for sleep and opioid withdrawal. Its name suggests a straightforward sleep effect, but human results have been inconsistent and the mechanism remains uncertain. In July 2026, Emideltide was the only one of seven peptide families that PCAC did not recommend for inclusion on the 503A Bulks List. Restorative Compounding Pharmacy + Wellness does not currently compound or dispense Emideltide/DSIP. PCAC did not recommend it for inclusion, and it is not FDA approved.

Key takeaways

• Emideltide is the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

• It is commonly called DSIP, or delta sleep-inducing peptide.

• It has been studied for insomnia, sleep architecture, narcolepsy, opioid withdrawal, pain, and stress.

• Human studies are small, older, and inconsistent.

• FDA evaluated chronic insomnia, narcolepsy, and opioid withdrawal.

• PCAC voted 6–7 against recommending Emideltide, with an abstention reported.

What is DSIP?

DSIP is a nine-amino-acid peptide originally isolated in research involving cerebral venous blood in rabbits during induced sleep. Its official nonproprietary name is Emideltide. The sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. FDA considered Emideltide free base and acetate as separate bulk drug substances.

The name “delta sleep-inducing peptide” can create the impression that its role is settled. It is not. Endogenous presence, physiologic function, receptor target, pharmacokinetics, and reproducible sleep effects remain debated.

How is Emideltide proposed to work?

Research has explored:

• slow-wave or delta sleep;

• sleep-spindle activity;

• opioid and enkephalin pathways;

• stress responses;

• circadian and neuroendocrine signaling;

• pain and withdrawal mechanisms.

No clearly established receptor-mediated mechanism explains all reported findings.

What is DSIP commonly promoted for?

• falling asleep faster;

• deeper or more restorative sleep;

• chronic insomnia;

• narcolepsy;

• opioid, alcohol, or other withdrawal;

• pain;

• anxiety and stress;

• cortisol regulation;

• recovery and growth-hormone support.

These are not FDA-approved uses.

What does the human research show?

Chronic insomnia

A small 1992 study in people with chronic insomnia reported higher sleep efficiency and shorter sleep latency with DSIP than placebo on objective measures: Bes F, et al. Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients (https://pubmed.ncbi.nlm.nih.gov/1299794/).
The study is of interest but is not enough to establish broad clinical use. Sample size, age of the evidence, dosing, formulation, reproducibility, and modern diagnostic standards limit certainty.

Opioid withdrawal

An older study explored DSIP during withdrawal and proposed possible opioid-receptor-related activity: Dick P, et al. DSIP in the Treatment of Withdrawal Syndromes (https://pubmed.ncbi.nlm.nih.gov/6548969/).
Modern opioid withdrawal treatment has established medications and protocols. Experimental peptide use should not displace evidence-based treatment or emergency care.

Narcolepsy

FDA evaluated narcolepsy, but the available evidence did not establish effectiveness. Narcolepsy is a complex neurologic disorder requiring specialized diagnosis and treatment.

What did FDA find?

FDA identified concerns involving:

• limited characterization of the free base and acetate;

• lack of a USP/NF monograph;

• no FDA-approved drug containing Emideltide;

• sparse historical compounding information;

• inconsistent and limited human evidence;

• uncertain mechanism and pharmacology;

• possible peptide impurities, aggregation, and immunogenicity;

• insufficient information to understand human safety.

FDA staff recommended against inclusion.
Read the FDA Emideltide briefing document (https://www.fda.gov/media/193344/download).

Why did PCAC vote against DSIP?

PCAC voted 6–7 against recommending Emideltide for the 503A Bulks List, with one abstention reported. Public accounts of the discussion emphasized:

• low-quality or insufficient efficacy evidence;

• poor characterization of the bulk substance;

• unresolved safety questions;

• availability of established therapies for several proposed uses.

This was a narrow vote, not a declaration that all future research is pointless. It means Emideltide did not obtain the favorable advisory recommendation received by the other six families.

Does the negative vote permanently ban DSIP?

Not necessarily. PCAC recommendations are nonbinding, and FDA makes the ultimate decision. Additional nominations, data, standards, studies, or future regulatory action could alter the record. As of this review, however, patients and providers should not describe Emideltide as recommended for 503A compounding.

Potential risks and unknowns

• inadequate modern human safety data;

• uncertain CNS and neuroendocrine effects;

• unknown interactions with sedatives, opioids, alcohol, antidepressants, or sleep medications;

• daytime impairment or altered sleep architecture;

• unknown pregnancy and pediatric risks;

• peptide impurities and immune reactions;

• sterile-product risks;

• delaying treatment for sleep apnea, narcolepsy, depression, substance-use disorder, or another underlying condition.

DSIP versus Epitalon

DSIP and Epitalon are both marketed for sleep but are different substances with different evidence:

• Length — DSIP/Emideltide: 9 amino acids. Epitalon: 4 amino acids.

• Main FDA-reviewed uses — DSIP/Emideltide: opioid withdrawal, chronic insomnia, narcolepsy. Epitalon: insomnia.

• July 2026 PCAC outcome — DSIP/Emideltide: not recommended. Epitalon: recommended.

• FDA approved? — Both: no.

Frequently asked questions

What does DSIP stand for?

Delta sleep-inducing peptide.

Is DSIP FDA approved?

No.

Did PCAC approve DSIP?

No. PCAC voted against recommending Emideltide for inclusion on the 503A Bulks List.

Does DSIP improve deep sleep?

Small older studies reported certain sleep changes, but the evidence is inconsistent and insufficient to establish a safe and effective therapy.

Can a pharmacy compound DSIP now?

The July 2026 process did not authorize it, and PCAC issued an unfavorable recommendation.

References

1. FDA. Emideltide-Related Bulk Drug Substances Briefing Document (https://www.fda.gov/media/193344/download).

2. Bes F, et al. Effects of DSIP on Sleep of Chronic Insomniac Patients (https://pubmed.ncbi.nlm.nih.gov/1299794/).

3. Dick P, et al. DSIP in the Treatment of Withdrawal Syndromes (https://pubmed.ncbi.nlm.nih.gov/6548969/).

4. FDA. July 2026 PCAC Meeting (https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026).